Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide
about
New and emerging disease modifying therapies for multiple sclerosisDevelopment of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, Fingolimod will change therapeutic paradigm approachTeriflunomide for multiple sclerosisTeriflunomide for multiple sclerosisTeriflunomide for multiple sclerosisInhibition of human DHODH by 4-hydroxycoumarins, fenamic acids, and N-(alkylcarbonyl)anthranilic acids identified by structure-guided fragment selectionMultiple sclerosis--new treatment modalitiesDevelopment of oral immunomodulatory agents in the management of multiple sclerosisLeflunomide reduces proliferation and induces apoptosis in neuroblastoma cells in vitro and in vivoProteome analysis of Aspergillus fumigatus identifies glycosylphosphatidylinositol-anchored proteins associated to the cell wall biosynthesis.The role of the T cell in autoimmune inflammation.Glucan synthase complex of Aspergillus fumigatus.An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors.Emerging oral treatments in multiple sclerosis - clinical utility of cladribine tabletsOral therapies for multiple sclerosis: a review of agents in phase III development or recently approved.Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects.Inhibition of p70 S6 kinase (S6K1) activity by A77 1726 and its effect on cell proliferation and cell cycle progress.Oral disease-modifying therapies for multiple sclerosis.Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens.A refined analysis of superoxide production by mitochondrial sn-glycerol 3-phosphate dehydrogenase.Immunotherapy for De Novo renal transplantation: what's in the pipeline?An update of teriflunomide for treatment of multiple sclerosis.Review of teriflunomide and its potential in the treatment of multiple sclerosis.New oral drugs for multiple sclerosis.Teriflunomide and its mechanism of action in multiple sclerosis.Pathophysiology of multiple sclerosis and the place of teriflunomide.Emerging oral drugs for relapsing-remitting multiple sclerosis.Emerging disease-modifying therapies in multiple sclerosis.Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis.Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis.Disease modification in multiple sclerosis: an update.Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective from Qatar.Leflunomide suppresses growth in human medullary thyroid cancer cells.In vitro evaluation of physiologically relevant concentrations of teriflunomide on activation and proliferation of primary rodent microglia.Leflunomide inhibits transendothelial migration of peripheral blood mononuclear cells.Teriflunomide attenuates immunopathological changes in the dark agouti rat model of experimental autoimmune encephalomyelitis.Suppressive effect of leflunomide metabolite (A77 1726) on metalloproteinase production in IL-1beta stimulated rheumatoid synovial fibroblasts.Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis.Teriflunomide promotes oligodendroglial differentiation and myelination.Control of hyperglycemia in male mice by leflunomide: mechanisms of action.
P2860
Q22242305-04E7C401-8772-4E76-B780-5D55F6AC52DAQ22305854-973A1627-EDB3-46FF-B320-AB67A3D4D199Q24186016-9A71F9D9-6F06-4536-8AEF-A280CE41FA49Q24198146-F671F426-5F9C-437B-AE91-64624F723528Q24202177-C0E156D9-820A-40DB-B603-2D911D0B91CBQ27660047-D305A3CF-1C14-48DD-84D8-2E96D16C5742Q28072906-6E0967AF-1639-4536-AA40-B50FD1169E0CQ28388704-A1462AFE-DB3E-4EB3-BAE9-C49CA7ED922FQ28535313-FB705AC4-379E-4476-A444-9F0B7EC092F6Q30712261-012FCF79-82E0-40D7-B7DB-0D8BC73BD8F6Q33709343-92D2624B-2F60-47D8-B3EE-119F739C71FDQ33995915-7C4C1D3F-BAB1-422A-A0C8-1577D5F927DAQ34066654-BB8FB9BD-FCA9-4161-A4F4-C5A4632E8719Q34133316-0067F25E-0114-4B4A-A916-0FADDD669476Q34153221-DE4151D1-FE5B-4456-8B7E-3CFA51C61B2CQ34389332-5E791A8B-1329-4616-9580-18411421D12CQ34417518-9C3252F7-0171-4E79-837D-F3EDC49FE86DQ34996562-C87F53E6-634A-43F8-8F03-C857DA2E474BQ35105760-71E39918-810E-4024-B9F0-119C11504394Q36466769-858A4B31-B168-4069-989D-CFBA29AC4E1CQ36595129-98356D2D-B7BE-4866-BFED-61965D9726A2Q36906008-E431BD54-FCFB-4629-818C-9273883DEB96Q37235715-4D9E10A6-4104-422E-B5AC-CFC91AD4E4BAQ37625921-924EF1D5-23D5-4D01-902A-876B89DA7A28Q37730005-CED4F999-35FE-4314-9E75-36EDD57E60C5Q37794267-7A6B1D7E-E09F-4838-BCA4-C2A5EBC99524Q37965547-A85C42EF-55B9-4503-86FD-B3C0F8113A76Q37994555-53A558EF-6F2F-497E-AC1B-7700E7AD5D7BQ38107524-BA3C0BE7-0076-4033-8392-C30CBAA7C2CEQ38117110-9379BBCB-C6C5-4B21-AA48-528A8A934B75Q38150823-D3A14E8B-D846-4F1B-9D94-E4BD11D2C632Q39021942-0A335B47-C4C5-488F-9E71-69F319D7606CQ39132342-28E18923-E32D-4DDE-BBED-869516798A9BQ41167409-712B4C15-BD09-4185-A333-02AF95A58EFEQ41823791-5646E633-811C-4A39-9793-AEA4A7EA5C96Q41877062-12477122-06CD-422A-9591-C163BF8C0FACQ45024320-D2727ED6-6021-4016-B5BA-7FE73B3603C9Q46147015-6C6A476D-A5B3-4AEC-B312-003C36BC1B03Q52657615-77472D85-201F-43A6-B269-CF0DDA90DB06Q52678340-459DD787-FFDD-44F0-87BF-291B5A00A3F3
P2860
Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Purification of human dihydro- ...... tive metabolite of leflunomide
@en
type
label
Purification of human dihydro- ...... tive metabolite of leflunomide
@en
prefLabel
Purification of human dihydro- ...... tive metabolite of leflunomide
@en
P2093
P2860
P356
P1433
P1476
Purification of human dihydro- ...... tive metabolite of leflunomide
@en
P2093
Bruneau JM
Spinella-Jaegle S
Westwood R
Williamson RA
Woodward K
P2860
P304
P356
10.1042/BJ3360299
P407
P478
336 ( Pt 2)
P577
1998-12-01T00:00:00Z